Part B: Patients must have either measurable disease or must be evaluable for MIBG response without evidence of Response Evaluation Criteria in Solid Tumors (RECIST) measurable lesions; patients with neuroblastoma in bone marrow only are not eligible
At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 will be allowed
At least one measurable disease site (as defined by Response Evaluation Criteria in Solid Tumors [RECIST]1.1) that has not been previously irradiated
Measurable or evaluable disease using Response Evaluation Criteria in Solid Tumors
Women with metastatic breast cancer, measurable or evaluable disease including bone metastasis only (as per the Response Evaluation Criteria in Solid Tumors [RECIST] v1.1)
Presence of measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1
Patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 =< 28 days prior to registration
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable or evaluable disease defined by Response Evaluation Criteria for Solid Tumors (RECIST) ver. 1.1
Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator
Measurable disease, as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease per response evaluation criteria in solid tumors.
Presence of measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Presence of measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 is acceptable, except to be eligible for the Part II fulvestrant-naive ER+ cohort, at least one measurable disease by RECIST 1.1 is required
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
The patient must have radiographic measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in dose escalation; measurable disease by RECIST 1.1 is required in dose expansion
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.
Measurable disease is required per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
At least 1 site of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Subjects must have measurable disease (Response evaluation criteria in solid tumors (RECIST 1.1))
Measurable disease is required according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
PART I: Patients must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present
Subjects must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Subjects must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
Have advanced cancer (metastatic, recurrent or locally advanced) and measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)1.1
Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; stage IV or recurrent disease is required
Presence of at least one lesion with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria for response assessment
Measurable and evaluable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator
Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Participants must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Patients must have evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 limited to the abdomen and pelvis
Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present
Subjects must have measurable disease on physical exam or imaging per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
At least one measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1), local or distant
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable or evaluable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease (either primary site and/or nodal disease) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 criteria
Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Tumor burden must be radiographically measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Must have measurable disease (by Response Evaluation Criteria In Solid Tumors [RECIST] 1.1 for those with solid tumors; by Lugano classification for those with NHL), except those with AML, who must have histologically confirmed relapsed or refractory disease.
Disease must be measurable with at least 1 unidimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
At least 2 metastatic sites of which at least 1 must be measurable as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within 28 days prior to registration
Has measurable disease according to Response Criteria for Solid Tumors (RECIST v.1.1)
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for patients with solid malignancies
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have measurable disease by modified Response Evaluation Criteria in Solid Tumors (RECIST) or RECIST; examinations for assessment of measurable disease must have been completed within 28 days prior to registration
Subjects must have measurable disease on physical exam or imaging per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Have measurable or unmeasurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; however, note that patients in Cohort 1 that have undergone an R0 resection will be eligible for the trial
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable or evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Subjects with measurable disease, progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable or evaluable disease based on modified Response Evaluation Criteria in Solid Tumors (RECIST) for mesothelioma
Presence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients may have measurable disease only, non-measurable disease only, or both (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
Patient must have measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 within 28 days prior to registration
Evaluable or measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, and meet the requirements for the intended study cohort
Presence of measurable recurrence, with Response Evaluation Criteria in Solid Tumors (RECIST) measurable disease at the time of intervention consent
Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; subjects with evaluable, but not measurable disease will be eligible for phase I
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients with advanced, measurable metastatic EGA, by Response Evaluation Criteria In Solid Tumors (RECIST) criteria
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
Patients must have measurable disease, defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
At least one measurable site of disease (as defined by Response Evaluation Criteria in Solid Tumors)
Presence of at least one site of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors 1.1
Patients must have at least one site of measurable disease (if applicable) (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 for solid tumors or the appropriate disease classification/criteria for the target population)
Measurable or evaluable disease based on the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria
Patients may have either measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
At least one measurable site of disease (as defined by Response Evaluation Criteria in Solid Tumors), or other disease specific response assessment criteria, as appropriate (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or physical exam
A minimum of one measurable lesion defined as: \r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, bone only metastatic disease may be allowed on approval from study principal investigator (PI)
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Evaluable disease for dose escalation, measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for dose expansions
At least two sites of disease that are measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Radiographically measurable disease present per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
At least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
At least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST).
Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable recurrence or metastases, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria for mesothelioma
Presence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (not required for Part 1); presence of evaluable OR measurable disease for Part 1
Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
CA-125 only disease without Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable or otherwise evaluable disease
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease, i.e., at least one measurable lesion as per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria only for expansion cohorts
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Histologically confirmed, measurable or evaluable disease; patients should have at least one measurable lesion; if applicable, Response Evaluation Criteria in Solid Tumors (RECIST) criteria should be used
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
All patients must have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have at least one site of measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria)
Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) or non-measurable disease, with measurement obtained within 4 weeks of registration
At least one site of measurable disease as determined by the Investigator, using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
The disease is evaluable by imaging per Response Evaluation Criteria in Solid Tumors 1.1.
Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or Lugano Classification for subjects with DLBCL.
Have measurable or non-measurable, evaluable disease by the revised response evaluation criteria in solid tumors (RECIST) v.1.1
Measurable disease that is evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Patients must have disease that can be evaluated radiographically, this may be measurable disease or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 9.3 criteria
Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable or non-measurable disease (but radiologically evaluable) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
Patient must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines
Evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
At least one measurable lesion by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST).
Measurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or bone-only disease
Patients must have measurable disease by modified Response Evaluation Criteria in Solid Tumors (RECIST) or RECIST; examinations for assessment of measurable disease must have been completed within 28 days prior to registration
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measureable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 or bone-only non measurable disease.
Measurable or evaluable disease will be included as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or bone-only disease
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST)
Patients must have disease (measurable or non-measurable acceptable) according to Response Evaluation Criteria In Solid Tumors (RECIST) v.1.1 criteria
Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Have the presence of measureable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Subjects with solid tumors, with the exception of castration-resistant prostate cancer (CRPC), must demonstrate measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measureable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 criteria
Subjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Part 2 only: Measureable tumor (Response Evaluation Criteria In Solid Tumors [RECIST] 1.1)
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
All patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have evaluable or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for solid tumors
Measurable tumor (by Response Evaluation Criteria in Solid Tumors [RECIST] criteria)
Must have measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease by computed tomography (CT) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 to evaluate response
Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable or nonmeasurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Progressive NSCLC: Defined as increasing measurable disease, or the appearance of new measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria despite treatment.
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients with measurable or non-measurable metastatic disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable or non-measurable (but radiologically evaluable) disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria 1.1.
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Subjects must have measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in the previously irradiated field
Must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable disease by (Response Evaluation Criteria in Solid Tumors [RECIST 1.1]) or evaluable disease
Evidence of unidimensionally measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST)
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable disease according to Response Evaluation Criteria in Solid Tumors [RECIST 1.1];
Measurable or non-measurable (but evaluable) disease as defined via Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
EXPANSION COHORT ONLY: Participants must have measurable disease, defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Patients must have disease that can be evaluated radiographically; this may be measurable disease or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST).
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) outside of any prior radiation field.
Patients must have measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients may have no evidence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria or have measurable disease; CA-125 and other available markers will be obtained
Measurable disease as measured by response evaluation criteria in solid tumors (RECIST) criteria v 1.1.
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Evaluable or measurable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST).
Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
Patients must have measureable disease at screening by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria
Measurable disease based on modified Response Evaluation Criteria In Solid Tumors (RECIST)
Subjects must have evaluable or measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable by Response Evaluation Criterion in Solid Tumors (RECIST) or evaluable disease.
Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) For multiple myeloma only:
Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1
Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1
Progression in measurable disease Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at the time of study entry
All patients enrolled will be required to have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria outside the radiation field
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Radiographically evaluable (measurable or non-measurable) disease (according to modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria
Presence of either evaluable disease or measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
The subject has measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Subjects must have measurable disease (Response evaluation criteria in solid tumors (RECIST 1.1)
Patients with measurable or non-measurable disease according to the response evaluation criteria in solid tumors (RECIST , v1.1)
Evaluable or measurable disease per response evaluation criteria in solid tumors (RECIST) v.1.1
Patients with measurable or evaluable disease according to the response evaluation criteria in solid tumors
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Soft tissue disease progression as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Presence of at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)
Disease that is measurable per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have measurable or evaluable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Histologically confirmed, measurable or evaluable disease; if disease is measurable Response Evaluation Criteria in Solid Tumors (RECIST) criteria should be used
Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Have measurable disease based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1
Patients must have measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Phase Ib: Have evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at the time of study entry
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1, see Section 9)
Have measurable disease based on Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)
Patients must have measureable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Has measureable disease by Response Evaluation Criteria In Solid Tumors (RECIST)
Has measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria at presentation
Have presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Subjects must have measurable disease preoperatively, defined as at least 1 contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm, as per RANO criteria
Pathologic criteria:
Have measurable disease based on RECIST 1.1 including at least two cancerous deposits; at least one deposit must be RECIST measurable while at least one deposit must meet criteria for SBRT; non-radiated tumor will be identified prior to randomization on the protocol
Measurable disease based on Cheson 2007 criteria
For patients with solid tumors, one of the following must apply: a. Patient has measurable disease as defined by the immune-related response criteria (irRC), b. Patient has ovarian cancer and has disease evaluable by CA-125 only
Measurable disease as defined by the tumor specific relevant response criteria for the breast and other solid tumor cohorts (measurable disease is not required for enrollment in the prostate cancer cohort):\r\n* RECIST version 1.1 criteria\r\n* Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria\r\n* RANO criteria
Measurable disease by RECISTv1.1 criteria
Measurable disease, defined by the 2014 Lugano Classification Criteria
Measurable disease, defined by the Revised Response Criteria for Malignant Lymphoma
Have disease that can be clinically evaluated for improvement or progression. In the dose-expansion phase of the study, subjects must have disease that is measurable, as defined by the RECIST Version 1.1 criteria for solid tumors (Eisenhauer et al, 2009) or the Lugano criteria for lymphoma (Cheson et al, 2014).
Measurable disease per the Lugano criteria
Must have evaluable or measurable disease; subjects with lymphoma must have evaluable or measurable disease according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma must be present; lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy
Patients must have measurable disease by the Lugano criteria
Progression (according to 2006 IWG criteria) at any time after initiation of AZA or DAC treatment or Failure to achieve complete or partial response or hematological improvement (HI) (according to 2006 IWG) after at least six 4-week cycles of AZA or either four 4-week or four 6-week cycles of DAC administered or Relapse after initial complete or partial response or HI (according to 2006 IWG criteria)
Subjects must have received at least 1 and not more than 3 previous lines of treatment and have had a response to at least 1 prior Treatment in the past (i.e., achieved a minimal response [MR] or better) according to the IMWG uniform response criteria.
Measurable disease by physical examination or imaging as defined by RECIST v1.1 criteria or evaluable disease as defined by Gynecologic Cancer Intergroup (GCIG) CA125 criteria.
Diagnosis of neuroblastoma as defined per International Neuroblastoma Response Criteria
Complete or partial response to salvage chemotherapy by International Working Group (IWG) criteria
Have up to five measurable (by Response Assessment in Neuro-Oncology Criteria [RANO]) brain metastasis planned for stereotactic radiosurgery
Measurable disease by RANO criteria
Have measurable disease based on iwCLL or Lugano criteria
Must have evaluable or measurable disease; subjects with lymphoma must have evaluable or measurable disease according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma; lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy
Measurable disease as defined by modified PCWG3 using iRECIST criteria
Patients must have measurable disease by Response Assessment in Neuro-Oncology (RANO) 2010 criteria at the time of registration (pre-operative)
Complete or partial response by International Working Group (IWG) Working Group or International Conference on Malignant Lymphoma (ICML) criteria to maximum of one salvage line of chemotherapy without pre-HDT/ASCT salvage radiotherapy
Disease status: Subjects must have measurable or evaluable disease, by RECIST v1.1 ± Curie Scale Criteria or RANO/RANO-BM
Subjects must have failed hypomethylating treatment where \failure\ is defined as: Progression (according to 2006 International Working Group [IWG] criteria) at any time after initiation of the hypomethylating treatment OR Failure to achieve complete or partial response or hematological improvement (HI) (according to 2006 IWG) after at least 4 cycles treatment OR Relapse after initial complete or partial response or HI (according to 2006 IWG criteria).
Subjects must have received 1 or more prior therapies for this disease and have had stable disease or progressive disease based upon the criteria from the Revised Response Criteria for Malignant Lymphoma, or intolerable toxicities precluding further therapy with a prior regimen
Subjects must have measurable disease per Revised Response Criteria for Malignant Lymphoma
Measurable disease by the criteria proposed by the acquired immunodeficiency syndrome (AIDS) Clinical Trials Group Oncology Committee (for KS)
JUST PRIOR TO FIRST VACCINATION (WITHIN 21 DAYS): patients must have either measurable disease per Response Criteria in Solid Tumors (RECIST) version (v)1.1 or evaluable disease defined as an elevated tumor biomarker (CA19-9, carcinoembryonic antigen [CEA] or circulating free deoxyribonucleic acid [cfDNA] mutation); pancreatic cancer patients with an elevated tumor marker following a primary pancreatic surgery would be eligible
Participants must have evaluable or measurable disease in accordance with the International Working Group Guidelines for Lymphoma.
Have measurable disease based on RECIST 1.1 and immune related response (irRC) criteria
Have measurable disease based on immune related response criteria (irRC) criteria
PROTOCOL-SPECIFIC CRITERIA:
PROTOCOL-SPECIFIC CRITERIA:
Measurable or assessable disease according to the “Revised Response Criteria for Malignant Lymphoma” (Cheson et al., J. Clin. Onc., 1999)105; patients in complete remission with no evidence of disease are not eligible
Measurable or evaluable disease by RANO criteria (MRI) or Macdonald (CT) criteria
Measurable disease as per IMWG response criteria
Have measurable disease based on immune-related response criteria (irRC)
CONSOLIDATION CRITERIA:
MAINTENANCE CRITERIA:
Have measurable disease outside of biopsy site present per immune related (ir)RECIST criteria
Have measurable or evaluable disease, as defined in 2007 Revised Response Criteria for Malignant Lymphoma; HL patients must not be currently eligible for autologous stem cell transplant
Measurable unresectable melanoma at least 1 measurable lesion based on Immune-related Response Criteria (irRC)
Disease Related Criteria:
Regulatory Criteria:
Diagnosis of PMF according to the revised WHO criteria; or PET-MF or PPV-MF according to the IWG-MRT criteria
In the Phase 2 portion of the protocol only, subjects must have measurable disease according to response criteria appropriate for their type of cancer (as explained in Section 9.1).
Disease progression following an initial confirmed response of MR or better to the combination (according to IMWG response criteria).
Measurable disease per the IMWG response criteria
Disease that is measurable as defined by RECIST v1.1, mINRC, Revised Response Criteria for Malignant Lymphoma, RANO criteria (as appropriate) or evaluable by nuclear medicine techniques, immunocytochemistry techniques, tumor markers, or other reliable measures
Measurable disease by RANO criteria at progression;
At least one measurable lesion according to the International Working Group Response Criteria for Lymphomas; there must be measurable lymphadenopathy to follow with serial exam and/or imaging
Stopped initial treatment with MK-3475 after attaining an investigator-determined confirmed response according to RECIST1.1 response criteria
Histological confirmation of disease with documented disease relapse after the last therapy requiring treatment per the treating physician. Participants with lymphoma must have at least 1 measurable site of disease (Part 2 only). In addition, B-cell malignancy disease-specific criteria specified in the protocol must also be met
REGULATORY CRITERIA:
Must have achieved a response (partial response [PR] or better based on investigator's determination of response by the IMWG criteria) to at least 1 prior regimen in the past
Measurable or evaluable disease, as defined in 2008 Revised Response Criteria for Malignant Lymphoma; baseline scans used for measurement should be obtained within 30 days of registration, and baseline bone marrow biopsy and/or aspiration should be obtained with 90 days of registration
Patients taking ruxolitinib at the time of enrollment must be deemed to have had a suboptimal response (less than partial response per IWG criteria) to ruxolitinib single-agent therapy or deemed to have progression of disease (per IWG criteria)
Disease that is measurable by standard imaging techniques per RECIST and immune-related response criteria (irRC; all tumor types except lymphoma) or International Working Group (IWG) revised response criteria for malignant lymphoma (lymphoma only). For patients with prior radiation therapy, measurable lesions must be outside of any prior radiation field(s), unless disease progression has been documented at that disease site subsequent to radiation.
Measurable disease by RECISTv1.1 criteria
AML participants must have the following malignancy criteria: measurable and evaluable disease per tumor response criteria; ? 5% bone marrow blasts without alternate causality; and > 90 days since allogeneic stem cell transplantation relapse in participants relapsing after transplant
Cohort B-2: 1) B- cell follicular lymphoma Grade 1, 2, or 3a (WHO criteria) 2) Relapsed/refractory disease >= 2 lines separated by Progression, prior treatment (or not eligible for receiving) CD20 antibody 3) Measurable disease (IWG -Lugano 2014)
Patients must have measurable non-visceral lesion(s) that are evaluable by the modified World Health Organization (mWHO) criteria and immune-related response criteria (irRC).
MCL patients must have:\r\n* At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma\r\n* Received at least 1 prior standard therapy for MCL
At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma 2007
At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma
They must have recurrent melanoma with measurable or evaluable sites of disease, 1.0 cm or larger, in order to assess the response to treatment by the immune-related response criteria (irRC)
Recurrent NSCLC: Defined as the re-appearance of measurable disease, or the appearance of new measurable disease by RECIST Criteria after prior successful treatment or complete response.
Refractory NSCLC: Defined as achieving less than a complete response and having residual measurable disease by RECIST criteria after prior treatment with chemotherapy, targeted or small molecules, monoclonal antibodies or any combination of these.
PATHOLOGICAL CRITERIA:
DISEASE AND PRIOR STATUS CRITERIA:
Measurable or evaluable disease, as defined in 2008 Revised Response Criteria for Malignant Lymphoma
Measurable disease, defined by the revised lymphoma criteria (Cheson 2007)
Measurable disease is not required for this study, since the primary endpoint is complete pathologic response
Ovarian cancer, primary peritoneal, and fallopian tube participants in the Phase 1 and Phase 1-T portions of this trial must have either measurable cancer by RECIST 1.1 criteria or an elevated cancer antigen (CA)125 level at least twice the upper limit of normal on two separate occasions at least 1 day but not more than 3 months apart; at least one of the samples should be within 1 week of starting treatment; patients with both an elevated CA125 and measurable cancer will be followed by RECIST 1.1 criteria; patients with only an elevated CA125 level will be followed by modified Gynecologic Cancer Intergroup (GCIG) criteria
DIAGNOSTIC CRITERIA
TIER I SUBJECTS: Patients with relapsed follicular lymphoma with stable disease and no lymph node mass greater than 5 cm (in any one dimension) following at least two systemic chemotherapy and/or immunotherapy regimens; stable disease from pre-study regimen may be either a clinically determined response by the principal investigator or physician co-investigator member of the study team, or a measured response as per the response criteria of this protocol
TIER II SUBJECTS: Patients with follicular lymphoma who have achieved at least a partial response with an initial chemotherapy and/or immunotherapy regimen; response from pre-study regimen may be either a clinically determined response by the principal investigator or physician co-investigator member of the study team, or a measured response as per the response criteria of this protocol
TIER II SUBJECTS: Patients with follicular lymphoma who have stable disease and no lymph node mass greater than 5 cm (in any one dimension) following an initial chemotherapy and/or immunotherapy regimen; response from pre-study regimen may be either a clinically determined response by the principal investigator or physician co-investigator member of the study team, or a measured response as per the response criteria of this protocol
At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma
Must have achieved at least a minor response to any previous regimen according to adapted European Group for Blood and Marrow Transplantation (EBMT) criteria
Patients must have chemo-sensitive disease achieving at least partial response (Cheson 2007 criteria) to last chemotherapy
Chemo-refractory disease as determined by less than partial response (Cheson 2007 Criteria) to last chemotherapy
Four or more American College of Rheumatology (ACR) criteria as revised by Hochberg for the classification of SLE or 4 or more of the Systemic Lupus International Collaborating Clinics (SLICC) criteria
Radiologically measurable disease by immune-related Response Criteria (irRC).
They must have recurrent melanoma with measurable or evaluable sites of disease, 1.0 cm or larger, in order to assess the response to treatment by the immune-related response criteria
Applicable disease criteria
Measurable disease by International Working Group (IWG) response criteria for lymphoma
At least one measurable lesion per revised IWG Response Criteria
For expansion: documentation by established staging studies or clinical examination to have measurable metastatic disease per RECIST v1.1 criteria
Measurable disease by RECIST v1.1 for subjects with solid tumors without glioma, by modified RANO criteria for subjects with glioma, or by the revised IWG criteria for subjects with AITL
Measurable tumor lesions according to RANO working Group Criteria. a. In the case that there is \non-measurable\ disease due to a radical surgical resection during screening, the subject still qualifies if Inclusion #3(b) is met.
Measurable disease based on Cheson 2007 criteria
All of the criteria listed above
At least one measurable lesion according to international workshop lymphoma response criteria; there must be measurable lymphadenopathy to follow with serial exam and/or imaging
Relapse or disease progression following response to prior rituximab-based therapy, requiring treatment by 2007 Revised Response Criteria for Malignant Lymphoma (RRCML) guidelines.
Part A: Have the presence of measurable or nonmeasurable disease as defined by the RECIST v1.1 (Eisenhauer et al. 2009) or Revised Response Criteria for Malignant Lymphoma (Cheson et al. 2007) or have measureable disease for multiple myeloma.
Patients must meet one of the following two requirements:\r\n* Have achieved minimal response (MR) or stable disease (SD) in current treatment regimen after receiving a minimum of two cycles\r\n* Have a partial response but show a decrease less than 25% or an increase less than 25% in measurable disease over a two month period\r\n** NOTE: Patients may be refractory to primary therapy or relapsed and have measurable or assessable disease; (refractory disease is defined as anything less than partial response [PR] or progression within 60 days of completing therapy)
Measurable disease per IWG 2007 criteria.
Radiographically or clinically measurable disease with at least 1 target lesion per International Working Group (IWG) criteria for malignant lymphoma.
CRITERIA FOR SURVIVORS:
Measurable disease as defined by mINRC, RANO, RECIST v1.1, or evaluable by nuclear medicine techniques, immunocytochemistry, tumor markers, or other reliable measures
REGULATORY CRITERIA
Measurable disease as per IMWG response criteria
Disease that is either:\r\n* Radiologically-measurable or evaluable as define by tumor response criteria from and MSKCC-Institutional Review Board (IRB) approved clinic research protocol\r\n* Detectable by biopsy (eg, bone marrow) and/or peripheral blood assays obtained within 6 weeks of study enrollment
Documented evidence of progressive MM (based on the Investigator's determination according to the modified IMWG response criteria) on or after their most recent regimen.
At least one measurable lesion per revised IWG Response Criteria
Relapse/progression based solely on elevation of CA-125, in absence of measurable disease, according to irRECIST criteria.
Documented radiological evidence for disease progression (measurable or nonmeasurable) =< 12 months prior to enrollment\r\n* NOTE: If patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation; at least one measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST)
Patients must have newly diagnosed, stage IIA – IV disease and must be entered within eight weeks from surgery; they may have either measurable residual disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria, or they may have no measurable residual disease; OR, they must have biopsy-proven recurrent disease of any stage and have never received cytotoxic chemotherapy
Disease must be measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; disease that has undergone local therapy in the past 30 days is not considered measurable unless the investigator has documented progression despite the local therapy (for treatment phase)
Metastatic or unresectable disease and at least one measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) criteria; NOTE: Nephrectomy or ablation of the primary tumor is allowed prior to enrollment
Dose expansion phase only: must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 (those undergoing pre-treatment resection must have imaging assessment after resection to determine measurability)\r\n* Previously irradiated sites of tumor may be considered measurable if there is radiographic progression at that site subsequent to the time of completing radiation
At least 1 measurable target lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Participants enrolled in the Phase I portion must have evaluable disease; participants enrolled in the Phase II portion must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have evidence of radiographic disease progression within the past 12 months; progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria is not required
Has measureable disease by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) 1.1 criteria.
Dose expansion only: Subjects must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria; this lesion must be outside a previously irradiated area
For Part 1: Participant must have evaluable disease. For Part 2: Participant must have measurable disease according to Response Criteria in Solid Tumors (RECIST) v1.1
Must have at least one measurable lesion per irRECIST (immune-related Response Evaluation Criteria Criteria in Solid Tumors):
Evaluable disease, either measurable on physical examination or imaging by Response Evaluation Criteria in Solid Tumors (RECIST v1.1, Appendix 2), or by informative tumor marker(s).
For Parts A, B, C, D, E, and F: Have either measureable disease or nonmeasureable but evaluable bone disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
At least 1 measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) meeting the following criteria:
At least one target lesion based on the evaluation criteria in solid tumors (RECIST 1.1).
Participants must have at least one lesion that is not within a previously radiated field that is measurable on computerized tomography (CT) or magnetic resonance imaging (MRI) scan per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; bone lesions are not considered measurable by definition
Has ?1 distant and/or discrete non-injected lesion that is amenable to biopsy via visual inspection or amenable to biopsy via image guidance, such as ultrasound or computed tomography/magnetic resonance imaging (CT/MRI). This lesion must be measurable as defined by the response criteria used to assess the participant (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] for solid tumors or revised International Working Group [IWG] criteria for lymphomas).
Dose escalation cohorts of FAZ053 single agent and FAZ053 in combination with PDR001: Patients with advanced/metastatic solid tumors with measurable or non-measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 who may or may not have received prior treatment with an immune checkpoint inhibitor, who have progressed despite standard therapy, or for whom no standard therapy is available.
Assessable disease status defined by Cheson (for lymphoma) or modified severity weighted assessment tool (mSWAT) (for mycosis fungoides [MF] and Sezary syndrome [SS]) criteria, or having measurable tumors defined by Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1) (for solid tumor)
Part A (all cohorts): Have the presence of measureable and /or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
The patient must have disease that is measurable by standard imaging techniques, per the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), or evaluable per RECIST 1.1. (For patients with prior radiation therapy, measurable lesions must be outside of any prior radiation field[s], unless disease progression has been documented at that disease site subsequent to radiation.)
Tumor size is measurable - measurable tumor criteria will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Measurable metastatic melanoma with at least one lesion that is resectable for TIL generation and at least one other lesion that can be measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have MBC that is measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Patients with metastases limited to the bones are eligible.
Patients must have measurable disease, documented according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, or evaluable disease with a standard tumor marker (alpha-fetoprotein [AFP] and/or human chorionic gonadotropin [HCG]) greater than 10 times the upper limit of normal
Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; for example, this would include tumor in the lung, liver, and retroperitoneum; bone disease is difficult to follow and quantify and as a sole site would not be acceptable
Patients may have disease that is measurable or non-measurable but evaluable disease (e.g. present on bone scan, rising tumor markers, non-measurable by Response Evaluation Criteria in Solid Tumors [RECIST] but visible on computed tomography [CT] scan); patients with third space fluid (for example pleural effusions) as only site of disease will not be eligible
Measurable metastatic (stage IV) gastric, gastroesophageal, pancreatic, hepatocellular carcinoma, cholangiocarcinoma, gallbladder, colorectal, urothelial, breast, ovarian/endometrial carcinoma, or glioblastoma  with at least one lesion that is resectable for TIL generation with minimal morbidity preferentially using minimal invasive laparoscopic or thoracoscopic surgery for removal of superficial tumor deposit, plus one other lesion that can be measured by Response Evaluation Criteria In Solid Tumors (RECIST) criteria
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) and obtained by imaging within 30 days prior to being registered for protocol therapy
Participants must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, including at least one tumor lesion that meets criteria for multi-organ site ablative radiation therapy (MOSART) SBRT radiation\r\n* 0.25 cc to 65 cc of viable tumor (i.e. primary disease of metastases) approximately 5 cm in maximal dimension; tumors larger than 65 cc can be partially treated\r\n* Metastases located in lung, liver, mediastinal/cervical node, spinal/paraspinal, osseous, abdominal-pelvic (lymph node/adrenal gland)
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; radiographic tumor assessment performed within 28 days before treatment; target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site after the completion of radiation therapy
The participant has the presence of measurable and/or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria In Solid Tumors (RECIST Version 1.1). Response Assessment in Neuro-Oncology (RANO) Criteria or Macdonald Criteria should be used for CNS tumors.
Subjects must have received neoadjuvant chemotherapy (any number of cycles) with complete or partial response as assessed by Response Evaluation Criteria in Solid Tumors 1.1 (RECIST)
Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST)1.1 or pure lytic or mixed lytic-blastic bone lesions
Metastatic disease of at least two non-central nervous system (CNS) sites (including the index lesion to be treated) measurable by RECIST criteria with at least one site outside of the radiation field and evaluable by RECIST criteria for evaluation of response
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; patients without measurable disease may be included on study after discussion with the sponsor, given that the primary endpoint of the study is Ki-67 of TIL (flow cytometry)
In dose expansion, at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 which can be followed by CT or magnetic resonance imaging (MRI)
Subjects must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Radiographic tumor assessment performed within 28 days of study inclusion.
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and be able to be followed over time by Immune related response criteria (irRC) for treatment decisions
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 including at least two metastatic lesions that meet criteria for SBRT radiation\r\n* 0.25 cc to 65 cc of viable tumor (i.e. primary disease or metastases) approximately 5 cm in maximal dimension; tumors larger than 65 cc can be partially treated
The subject has a biopsy-proven diagnosis of adenocarcinoma of the pancreas (or recurrence of previously resected disease) with metastatic disease that is measurable per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Must have measurable disease by radiographic or physical criteria suitable for evaluation according to RECIST v1.1 for documentation of disease response or progression.
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Metastatic disease that is evaluable radiologically by Response Evaluation Criteria in Solid Tumors (RECIST) or MD Anderson criteria, which will allow for bone-only disease
Documented disease recurrence/progression based on Gynecologic Cancer Intergroup (GCIG)-Response Evaluation Criteria in Solid Tumors (RECIST)
Patients with the presence of at least one measurable lesion as defined by RECIST 1.1 criteria for response assessment
Subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria independent of the lesion irradiated
Have measurable disease with at least 1 unidimensional lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
For patients enrolled in arm A dose level 4, arm A 14-patients expansion cohort, and arm B (first stage of phase II of TRC102 and pemetrexed) measurable disease is required according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria for patients with solid tumors and modified RECIST criteria as described by Byrne and Novak for patients with malignant pleural mesothelioma; pleural effusion and ascites are not considered measurable disease
Progressive disease based on radiological imaging within 12 months; Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 would be used to assess measurable disease burden
At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria that has not been previously irradiated and which can be followed by computed tomography (CT) or magnetic resonance imaging (MRI)
Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1; baseline measurements and evaluations must be obtained within < 4 weeks of enrollment; disease in previously irradiated sites is considered measurable if there has been unequivocal disease progression or biopsy-proven residual carcinoma following radiation therapy
All patients must have measurable lesions according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 must have at least 1 tumour lesion amenable to biopsy, and must be medically fit and willing to undergo a biopsy before first treatment and, unless clinically contraindicated, after 6 weeks on therapy
Patients with metastasis outside of the abdominal cavity; except\r\n* Disease outside of the abdomen that is non-measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria will be allowed
At least one clinically evaluable or uni- or bi-dimensionally measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
All patients must have evaluable disease as defined as:\r\n* Solid tumors must have a lesion evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1\r\n* Central nervous system tumors will be evaluated by Response Assessment in Neuro-Oncology (RANO) criteria\r\n* Leukemia patients must have > 10% blasts (or blast equivalent) in the bone marrow
At least one site of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria on computed tomography (CT) scan done within 30 days prior to study start
Have a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) and have at least one measurable lesion as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; the target lesion(s) should also have bi-dimensional measurability for RECIST 1.1 evaluation on study
Subjects, including those in the dose-escalation portion of the study, must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; imagining must be within 28 days of trial enrollment\r\n* Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site prior to trial enrollment
Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST); the measurable lesion(s) must be outside the field of radiation therapy (RT) if there was prior treatment with RT unless progression at the site has occurred
Have at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1); NOTE: Enrollment of patients with bone-only disease may be limited if we find we are not able to get adequate tissue for research correlates from bone biopsies
INCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients must have measurable disease by at least one of the criteria below:\r\n* Extra skeletal disease that can be accurately measured in at least one dimension as >= 10 mm with conventional computed tomography (CT) techniques as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\r\n* Skeletal or bone-only disease measurable by fludeoxyglucose F 18 (FDG) positron emission tomography (PET) imaging
Measurable or evaluable indicator lesion(s) as defined by RECIST v1.1; patients without RECIST measurable disease will be eligible for enrollment to \Other\ cohort provided their disease can be evaluated using another accepted response criteria (e.g. Gynecologic Cancer InterGroup [GCIG] CA125 response criteria, positron emission tomography [PET] Response Criteria in Solid Tumors [PERCIST])
Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 including at least two tumor lesions that meet criteria for multi-organ site ablative radiation therapy (MOSART) SBRT radiation\r\n* 0.25 cc to 65 cc of viable tumor (i.e. primary disease or metastases) approximately 5 cm in maximal dimension; tumors larger than 65 cc can be partially treated\r\n* Metastases located in lung, liver, mediastinal/cervical node, spinal/paraspinal, osseous, abdominal-pelvic (lymph node/adrenal gland)
Patient has measurable disease by RECIST version 1.1 (solid tumors) or Lugano (lymphoma) criteria or evaluable or measureable disease by Macdonald criteria (rHGG).
At least one Response Evaluation Criteria in Solid Tumors (RECIST)-defined target lesion; patient must have documented disease progression
Measurable or evaluable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; tumor lesions previously irradiated or subjected to other loco-regional therapy will only be deemed measurable if progression at the treated site after completion of therapy is clearly documented
Patients with any type of malignancies; and/or HIV/AIDs; and/or history of solid organ transplant; and/or Merkel polyoma-virus related Merkel cell tumor(s) with measurable disease on imaging per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have evidence of metastatic disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria or non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease; Note: measurable lesions include lytic or mixed (lytic + blastic) bone lesions, with an identifiable 10 mm soft tissue component that meets the measurability criteria per RECIST
Medically unresectable (stage I-II) or locally advanced (stage III); patients with distant metastases (stage IV) must have stable disease or improved disease (partial response, or complete response) per Response Evaluation Criteria in Solid Tumors (RECIST) criteria as determined on serial imaging following a course of chemotherapy
Patients must have evaluable disease – defined as one of the following:\r\n* Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable disease OR\r\n* Evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related) AND a cancer antigen 125 (CA125) that has doubled from the post-treatment nadir and is also greater than 2 times upper limit of normal (ULN)
Has clinical response or stable disease for minimum of two months (three cycles of every three week chemotherapy or 8 weeks of weekly regimen, etc.) after receiving any prior chemotherapy for metastatic/recurrent disease; a minimum of two cycles (6-8 weeks) of chemotherapy is required to determine clinical response; per Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1, clinical response for measurable disease is defined as complete response (CR) or partial response (PR); for non-measurable disease only (i.e. bone metastasis, ascites, pleural effusion, and pathological lymph nodes >= 10 to < 15 mm short axis) is defined as persistence of one or more non-target lesion(s) and no increase in overall tumor burden
Disease progression based on RECIST (Response Evaluation Criteria in Solid Tumors) criteria while the subject has been taking fulvestrant, and for which continuation of endocrine therapy would be appropriate
Histological diagnosis of ameloblastoma; all stages are eligible; patients must have evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Progressive disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator within the 12 months preceding study enrollment
All patients must have measurable or evaluable disease defined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria; if the patient has received prior radiation therapy one measurable lesion must be outside the irradiated field; lesions within an irradiated field will be followed as non-target lesions and considered evaluable; if the only site of measurable disease is within a previously irradiated field then 6 months must have elapsed between the completion of radiation therapy and entry on study to be considered measurable; if the specific diagnosis occurs radiologically as standard of care and a diagnostic procedure is too dangerous for any reason, subjects may be enrolled on study based on the presumptive radiographic diagnosis
At least one measurable lesion as assessed by computed tomography (CT) scan using Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Measurable metastatic disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria,\r\n* Must be amenable to ultrasound or computed tomography (CT)-guided biopsy of one metastatic lesion\r\n* Peritoneal disease as the sole site of occult metastasis or presenting as malignant ascites is acceptable if a cell block of tumor cells can be obtained showing > 20% viable tumor cells
Patients must have one target lesion to be utilized in order to assess response per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version (v)1.1\r\n* Lesions that have previously been treated with stereotactic radiosurgery (SRS) are excluded as measurable disease because distinction of radiation necrosis and tumor progression can be difficult in this setting and enlargement of the lesion may not necessarily mean progression
The target lesion(s) can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST)
The subject has a histologic or cytologic diagnosis of a DTC tumor (including poorly differentiated thyroid cancer but not anaplastic thyroid cancer) that is metastatic or unresectable and fulfills the following criteria:\r\n* Subjects must have progressive disease as defined by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) criteria when comparing baseline scans to those obtained within the prior 14 months AND\r\n* Subject must have radioiodine (RAI)-refractory disease based on at least one of the following:\r\n** Prior dose of RAI exceeding 600mCi\r\n** Progression of disease within 18 months following a dose of >= 100mCi\r\n** Presence of target lesions as defined by modified RECIST criteria which do not take up RAI
Patients are not required to have measurable disease by traditional Response Evaluation Criteria in Solid Tumors (RECIST) criteria, as lesions in the pancreas are notoriously hard to measure radiographically; however, patients must have disease which is evaluable for resection
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; at least one measurable lesion needs to be outside the field of prior therapeutic radiation or has progressed after radiation
Measurable tumor according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria with at least one unidimensionally measurable target lesion
Histologically proven pancreatic adenocarcinoma with measurable disease, defined as at least 1 unidimensionally measurable lesion on imaging as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (or for thymic carcinoma, at least one measurable lesion per International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 criteria
Radiographic evidence of metastatic disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria OR by prostate cancer-specific positron emission tomography (PET) imaging; evaluable non-target lesions and/or bone only metastasis are permitted per RECIST 1.1 and Prostate Cancer Clinical Trials Working Group (PCWG3) guidelines; non-target, pathological lymph nodes >= 10 mm and less than 15 mm in the short axis are permitted
The target lesion(s) can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumors (RECIST) and must have a maximum tumor volume of =< 100 cm^3
Stage II of the trial: evaluable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria must be present for all subjects in the randomized component of the trial– if surgery or radiation is planned, the target lesions may not be so treated until after the assessment of the effect of chemotherapy
Patients with progressive disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria by imaging techniques are not eligible to proceed to the second transplant; tumor marker increase alone is not sufficient to diagnose disease progression
Documented progression of disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, defined as any progression that requires a change in treatment, prior to randomization
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the site study team. Target tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions;
At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST v.1.1) in contrast enhanced (unless contraindicated) CT or MRI
Subject has measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; tumor lesions situated in previously irradiated areas are considered measurable if progression has been demonstrated in such lesions
At least one evaluable or uni- or bi-dimensionally measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1criteria; (patients whose only nodal disease is cystic and not positron emission tomography [PET]-avid are not eligible)
At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in contrast enhanced (unless contraindicated) CT or MRI.
RENAL COHORT: Patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria in at least one site that is not the site for planned surgical resection or serial biopsy
Phase II only: Must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Metastatic disease in at least two distinct lesions (including the index lesion to be treated) with at least one site outside of the radiation field and evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for evaluation of response
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or at least one site of disease must be uni-dimensionally measurable as per RECIST 1.1. All radiology studies must be performed within 28 days prior to registration
Histologically proven metastatic pancreatic or colorectal adenocarcinoma with measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Bi-dimensionally measurable disease by radiographic imaging (computed tomography [CT] scan) that represents at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and obtained by imaging within 28 days prior to registration for protocol therapy; disease in an irradiated field as the only site of measurable disease is acceptable only if there has been clear progression since completion of radiation treatment
Patients must have a clinically measurable primary oropharyngeal tumor, defined as measuring >= 1 cm by spiral computed tomography (CT), per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, and/or by clinical examination
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1 and >= 1 site safe for biopsy
Subjects who have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 or elevated tumor markers (human chorionic gonadotropin [hCG], alpha-fetoprotein [AFP])\r\n* Note: patients without measurable disease are allowed on the study as long as they have clearly rising tumor markers and they will be exempt from biopsy
ARM A: Histologically or cytologically confirmed hepatocellular carcinoma that is refractory (by Response Evaluation Criteria in Solid Tumors [RECIST] or modified [m]RECIST criteria or with unequivocal clinical progression of disease) to or intolerant (defined as inability to administer further sorafenib due to drug related toxicities) of sorafenib based therapy or advanced solid tumor with liver predominant disease burden that has progressed on or is intolerant to standard
Subjects with extracranial disease must have evaluable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); subjects affected by glioma must have evaluable disease by Response Assessment in Neuro-Oncology Criteria (RANO) criteria
Patients with confirmed diagnosis of ECD that are asymptomatic and with no visceral involvement are not eligible for this trial (patients with no target lesions as per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria)
Must have a minimum of 3 radiographically distinct (> 1.5 cm) lesions measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at time of study enrollment (> 5 preferred)\r\n* A maximum of 2 metastases per treated organ may be targeted for HD-XRT, but must be separated by more than 5 cm of normal tissue\r\n* At least 2 non-irradiated lesions are required for systemic response assessments
Participants must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria or evaluable cancer via cancer antigen (CA)125 Gynecologic Cancer Intergroup (GCIG) criteria
Patients enrolled in the dose expansion phase must have at least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for solid tumors or measurable nodal disease at baseline as defined by Cheson criteria for lymphoma
Measurable or evaluable disease as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for non-GBM tumors and by Response Assessment in Neuro-Oncology (RANO) criteria for GBM
Evaluable disease, as follows:\r\n* For phase IA dose escalation: have the presence of any evaluable disease, including bone metastases, effusion, or cystic metastases\r\n* For phase IB extension only: have progressive and measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v 1.1)
Patients must have measurable or non-measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to registration (Phase I)
Non-measurable and/or measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, or abnormal cancer antigen (CA)-125 to levels (in patients with ovarian cancer) at least 1.5 x normal documented by two independent measurements at least 4 weeks apart
Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) criteria; X-rays, scans or physical examinations used for tumor measurement must have been completed within 28 days prior to registration; X-rays, scans or other tests for assessment of non-measurable disease must have been performed within 42 days prior to registration
Has at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as confirmed by the blinded central imaging vendor.
At least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria for response assessment (certain exceptions may apply)
Measurable or non-measurable (but radiologically evaluable) disease per Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 on computed tomography (CT) scan (within 28 days of randomization) with at least one lesion outside previously irradiated areas.
Patients in the phase II portion must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; previously irradiated sites can be included if there is documented progression of disease in that site; patients in the phase I portion do not require measurable disease by RECIST 1.1 criteria
At least one site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) criteria that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation
Participant must have at least 1 unidimensional measurable NSCLC lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1).
As defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the Revised Response Criteria for Malignant Lymphoma or the Response Assessment in Neuro Oncology (RANO) criteria for glioblastoma:
Have at least one untreated and progressing tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumor
Must have measurable tumor per Response Evaluation Criteria In Solid Tumors (RECIST) or modified RECIST for malignant pleural mesothelioma
Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens including but not limited to cancer antigen (CA-125) and prostate-specific antigen (PSA).
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1; previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation; the pleural mesothelioma cohort will require measurable disease according to modified RECIST
Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as confirmed by the blinded central imaging vendor
Has measurable disease at baseline based on Response Evaluation Criteria is Solid Tumors (RECIST) 1.1 as determined by the central imaging vendor
Measurable disease as defined by Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST).
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) (Response Evaluation Criteria in Solid Tumors [RECIST] criteria 1.1)
Have either measureable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Measurable disease according to modified RECIST (Response Evaluation Criteria In Solid Tumours) criteria
Patients with at least one measurable skin metastases and distant, measurable metastases (outside of skin) by Response Evaluation Criteria in Solid Tumors (RECIST); for patients without distant measurable metastases, an area of the skin metastases designated to not receive local therapy can be substituted; patients with multiple (>= 2) metastatic sites (skin involvement not required), with at least one site measurable by RECIST, will be eligible for the CTX/RT cohort
At least one site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria that has not been previously irradiated; if the patient has had previous radiation to the target lesion(s), there must be evidence of progression since the radiation
The patient must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 and must have one site amenable to biopsy that, in the opinion of the investigator and/or interventional radiologist, is likely to yield acceptable tumor sample for a core biopsy per the above pathology criteria
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria or any other baseline prerequisite for the assessment of the principal judgement criteria
Have a diagnosis of NSCLC with at least 1 measurable lesion assessable using standard techniques by the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
Presence of measurable or nonmeasurable but evaluable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1, Eisenhauer et al. 2009).
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by computed tomography (CT) scan, or for skin lesions not measurable by CT scan, measurements may be performed with caliper or flexible ruler\r\n* Note: stage IV no evidence of disease (NED) is excluded by this criterion
Patients should have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; if no measurable disease is present, patients should have assessable disease such as pleural effusion, ascites, with cancer antigen 125 (CA125) Gynecological Cancer Intergroup (GCIG) criteria
Measurable disease per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; a lesion in a previously irradiated area is ineligible to be considered as measurable disease unless there is objective evidence of progression of the lesion prior to study enrollment
Subject must have at least 1 unidimensional measurable NSCLC lesion on a Computerized Tomography (CT) scan as defined by Response Evaluation Criteria In Solid Tumors (RECIST - version 1.1).
Measurable disease by Computed tomography (CT) or Magnetic resonance imaging (MRI) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria
Measurable (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) indicator lesion not previously irradiated
At least one measurable metastatic lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria; ascites, pleural effusions, and bone metastases are not considered measurable; minimum indicator lesion size = 10 mm by helical computed tomography (CT) or = 20 mm by conventional techniques; pathological nodes must be = 15 mm by the short axis to be considered measurable
No disease progression (i.e. stable disease [SD] or better response by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) at the completion of chemotherapy.
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1, which includes locoregional lesions (not amenable to curative surgery and/or radiation) and distant metastatic lesions
Patients must have at least one tumor lesion that meets the following criteria: the lesion can be accurately measured in at least one dimension according to Response Evaluation Criteria in Solid Tumor (RECIST)
Measurable tumor according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria with at least one unidimensionally measurable target lesion
One or more measurable metastatic tumors measurable on CT san per Response Evaluation Criteria in Solid Tumors (RECIST v.1.1 ), excluding the primary lesion.
Evidence of metastatic disease with measurable lesion(s) as defined by RECIST guideline version 1.1 to permit tumor response evaluation; subjects with unresected primary tumors may be enrolled as long as evidence of measurable metastatic disease is also present
Patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; baseline measurements and evaluations of all sites of disease must be obtained =< 4 weeks prior to randomization and must be acquired by multiphasic CT or contrast magnetic resonance imaging (MRI)
Progressive disease after androgen deprivation, as defined by Prostate Cancer Working Group 2 and/or Response Evaluation Criteria in Solid Tumors criteria
Patients must have at least one site of measurable disease (if applicable) (per RECIST for solid tumors or the appropriate disease classification/criteria for the target population)
Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
At least one clinically evaluable or uni- or bi-dimensionally measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patients must have a primary or metastatic lesion measurable in at least one dimension by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1 within 4 weeks prior to entry of study
Measurable disease by Response Evaluation Criteria in Solid Tumors- (RECIST) 1.1 criteria; previous irradiated tumor is acceptable if there is at least a 20% increase in the size of the previously irradiated lesion
In continuous complete or partial remission or stable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) after standard first-line treatment.
As defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) or the Revised Response Criteria for Malignant Lymphoma
Patient on the dose-escalation portion of the trial must have evaluable disease, defined as either measurable (by Response Evaluation Criteria in Solid Tumors [RECIST]) or non-measurable disease (e.g. bone mets, pleural effusion or lymphangitic spread); measureable disease is required for patients in the expanded RP2D cohort
Have the presence of measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). A lesion that has been previously treated by local therapy will qualify as a measurable or evaluable lesion if there was demonstrable progression following locoregional therapy
Patients may be registered on study prior to completing all chemotherapy but only those having a response or stable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria after 3 to 6 cycles of first-line chemotherapy may proceed on study with SBRT/radiation therapy (RT) treatment
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 besides the tumor that is expected to be radiated; bony lesions without soft tissue component are not measurable lesions
Patient has at least one measurable nodal lesion (>= 2 cm) according to Response Evaluation Criteria in Lymphoma (RECIL) criteria
Measurable and/or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and/or Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria; bone only disease is allowed
Patient must have at least 1 site of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria on computed tomography (CT) or magnetic resonance imaging (MRI) which will not be irradiated
At least 1 measurable target lesion according to Response Evaluation in Solid Tumors (RECIST) 1.1
Measurable (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) indicator lesion not previously irradiated
Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with progressing or new tumors since last antitumor therapy
Have at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
Have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. CRPC participants may be enrolled with objective evidence of disease as per Prostate Cancer Working Group (PCWG2) criteria
Measurable indicator lesion by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Subject has at least 1 measureable lesion (not including any lesion that was irradiated) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
At least one measurable lesion as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Patients must have at least one uni-dimensional measurable lesion by CT or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST)version 1.1. (applicable only in Phase 2)
At least 1 solid tumor lesion measurable by computer tomography (CT) scan or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Disease progression by PSA criteria (PSA Working Group Consensus Criteria Eligibility) and/or Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)-1.1 criteria; previous irradiated tumor is acceptable if there is at least a 20% increase in the size of the previously irradiated lesion
Patients must have evaluable disease; measurable disease is not required; however, if measurable disease is present, it is defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1; furthermore, if only evaluable disease is present, a relevant tumor marker (per investigator discretion) must be >= 2 times upper limit of normal (ULN) at baseline, and can be used as a response indicator
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
Have at least 1 extracranial metastasis that is amenable to radiation and at least 1 other site of disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Subjects must have at least two lesions:\r\n* At least one lesion must be safely amenable to irradiation and likely to meet criteria delineated in the judgement of the treating radiation oncologist; this can be a lesion that was previously irradiated as long as prior radiation was at least 6 months prior to projected first fraction of SBRT and as long as reirradiation dose constraints as outlined are being met\r\n* A separate, not-to-be-irradiated lesion measurable by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria
Patient’s disease must be bi-dimensionally measurable by caliper or radiological method as defined in the Response Evaluation Criteria in Solid Tumors (RECIST) criteria; for subjects with a single lesion, archived tissue must be available for research analysis; multiple superficial melanoma lesions must have an aggregate total diameter of >=10 mm
Have at least 1 measurable lesion outside of the central nervous system (CNS) whose presence is assessable using standard techniques by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Histologically proven pancreatic adenocarcinoma with measurable disease, defined as at least 1 unidimensionally measurable lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Patient must have previously progressed on abiraterone (either by PCWG2 criteria or Response Evaluation Criteria in Solid Tumors [RECIST] criteria)
Radiographically documented measurable disease at study entry per response evaluation criteria in solid tumours ( RECIST) v1.1.
Measurable (Response Evaluation Criteria In Solid Tumors [RECIST 1.1]) indicator lesion not previously irradiated
At least one target lesion that has not been treated with local therapy and is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Previously treated with trametinib on Arm A and experienced objective disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Patients must have achieved a complete response (CR) or partial response (PR), as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, following treatment for recurrent ovarian, fallopian tube, or peritoneal cancer; histological confirmation of the original primary tumor is required
Stage IV disease as evidenced by soft tissue, visceral and/or bony metastasis must be Response Evaluation Criteria in Solid Tumors (RECIST) evaluable on computed tomography (CT) scan and/or bone scan
Radiographically measurable disease; measurable disease is defined as disease that can be assessed with 2-dimensional measurements on a cross-sectional imaging; minimum lesion size is 2 cm in greatest diameter as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria
Subjects with advanced and/or metastatic solid tumors or B-NHL who are either refractory to or have relapsed from standard therapies, or for whom a standard therapy does not exist with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Documented progressive disease based on investigator assessment according to Response Evaluation Criteria in Solid Tumours (RECIST) following receipt of at least two cycles of cisplatin or carboplatin administered for R/M disease
Patients enrolled in the dose expansion phase must have at least one measurable lesion as defined by RECIST criteria for solid tumors or Measurable nodal disease at baseline as defined by Cheson criteria for Lymphoma.
Patients must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria that has not been previously irradiated; if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation
The participant must have a tumor measurable according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, measurable by elevated tumor markers (eg, 24-hour urine 5-HIAA, chromogranin A, adrenocorticotropin hormone (ACTH), gastrin, or other tumor specific biochemical markers), or both
Patients must have measurable disease either primary and/or metastatic masses reproducibly measurable in one or two diameters by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 parameters by CT scan or MRI scan; positron emission tomography (PET) or octreotide scans are useful adjuncts but will not be used to measure response
Documented radiological evidence for disease progression (measurable or nonmeasurable) =< 12 months prior to enrollment; NOTE: if the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation; at least one measurable lesion as per Response Evaluation Criteria In Solid Tumors (RECIST)
Cutaneous tumor deposits that, in the opinion of the investigator are amenable to sequential biopsies for correlative analyses; in addition to these, all patients must have measurable disease (i.e., present with at least one measurable lesion per Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1)
Symptoms uncontrolled by somatostatin analogues OR morphologically progressive tumor by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria in the liver OR baseline tumor burden > 25% of the liver volume
Have evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and/or Prostate Cancer Working Group 2 (PCWG2) criteria
Patients must have measurable or evaluable/non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1; patients with bone only disease are not eligible; NOTE: for patients with metastatic disease in the liver, tumor burden should not be deemed significant (e.g., to no more than 30% of total liver volume as assessed by local review/investigator)
Patients must have either measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) or evaluable disease (non-measurable lesions) outside irradiated field on computed tomography (CT)/magnetic resonance imaging (MRI)
Disease may be measurable (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) or non-measurable but must be present in at least one non-liver site, where presence is defined as 1.5 cm or greater and visualized on PET/CT with [18F]-fluorodeoxyglucose (FDG); patients with effusion only disease or disease only in the liver are not eligible for the study
At least one lesion measurable according to PET Response Criteria in Solid Tumors (PERCIST) v1.0: > 2 cm in diameter to avoid PET partial volume effects
At least one site of measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) that is seen on CT, magnetic resonance imaging (MRI), or FDG PET/CT
Disease may be measurable (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) or non-measurable but must be present in at least one non-liver site, 1.5 cm or greater and visualized on PET/CT with [18F]-fluorodeoxyglucose (FDG). Patients with effusion only disease or disease only in the liver are not eligible for the study.
Disease measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, a mass of greater than 1 cm in the long axis and/or other tumor response criteria from an MSKCC institutional review board (IRB)-approved clinical research protocol; NOTE: study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitment
Disease measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or other tumor response criteria from an MSKCC Institutional Review Board (IRB)-approved clinical research protocol; NOTE: Study patients do not need to be participating in an MSKCC approved clinical trial prior to study recruitment
Disease is measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) (1.1 or original version) or other tumor response criteria from an MSKCC Institutional Review Board (IRB)-approved clinical research protocol\r\n* This criterion does not apply to patients with myeloproliferative neoplasm; the presence of active myeloproliferative neoplasm will be determined by applicable disease-specific diagnostic criteria and patient assessment by the patient’s oncologist and trial investigators (eg, manifestations of active myeloproliferative neoplasm [MPN] such as splenomegaly, abnormal blood counts, etc)
Eligible adult patients currently meeting inclusion criteria and will be treated with an investigational or recently approved therapeutic agent at HCI; the patients must have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; RECIST imaging must be current and have been obtained within 30 days prior to the baseline imaging session
Subjects must have measurable disease by CT or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria; to comply with PET Response Criteria in Solid Tumors (PERCIST) criteria, subjects should have at least one lesion measuring at least 2 cm in the longest diameter
Presence of at least one measurable lesion according to modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Subjects are required to have measurable disease that has progressed through prior therapy and that includes a non-hepatic lesion for imaging that is >= 1.5 cm, as defined by modified Response Evaluation Criteria in Solid Tumors (RECIST)
Subjects must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Measurable disease according to RECIST v.1.1 (or Choi criteria and/or EORTC metabolic response criteria for solid tumors, in the case of GIST); or
Additional Inclusion Requirements for expansion cohorts only a) Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (Version 1.1) and at least 1 nonsignificant risk, non-target lesion accessible for biopsy per the guidelines above (for TAK-580 + nivolumab and TAK-202 (plozalizumab) + nivolumab only).
Measurable disease according to Immune-Related Response Evaluation Criteria In Solid Tumors (irRECIST)
Recurrent or metastatic disease, documented by imaging (CT scan, MRI, X-ray) and/or physical examination. In phase II, measurable disease as per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 is mandated. In phase Ib, patients with or without measurable disease are eligible.
The patient must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1).
Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
No metastatic disease on cross-sectional imaging (according to Response Evaluation Criteria in Solid Tumors [RECIST] version [v]1.1 criteria)
Patients must have radiographically measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
Measurable disease (at least one target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1);
Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria
Have measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
For all dose expansion arms, participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Presence of measurable lesions by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Palpable lesions that are not measurable by radiologic or photographic evaluations may not be utilized as the only measurable lesion.
Must have measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) at baseline
Measurable disease (i.e., present with at least one measurable lesion per Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1)
Measurable unresectable stage III or IV malignant melanoma and Response Criteria in Solid Tumors (RECIST), version 1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Must have at least 1 measurable lesion assessable using standard techniques by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Phase I: Patients with advanced/metastatic solid tumors, with measurable or unmeasurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST version [v]1.1); baseline measurements must be obtained within 4 weeks prior to registration
Have evidence of measurable disease (according to Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1)
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and Immune related Response Criteria (irRC).
PHASE I: Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria.
Measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1), modified RECIST or Revised Response Criteria for Malignant Lymphoma
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)
Participants must have at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 that is amendable to biopsy.
Measurable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteria.
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
Measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria
Histologically and/or cytologically confirmed and radiographically measurable per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 colorectal cancer with liver metastasis. Patients may have other sites metastatic disease.
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Presence of measurable disease by computed tomography (CT) scan per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
At least one measurable tumor lesion as defined by Response Evaluation Criteria in Solid Tumors (Response Evaluation Criteria in Solid Tumors [RECIST]) version (v)1.1 criteria
Measurable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST1.1)
Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
For dose expansion phase, patients must have at least one site of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1)
Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1
Patients must have at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.)1.1, determined by investigator review
Subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.
Has measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for patients with solid malignancies and evaluable disease as assessed by bone scan and/or positron emission tomography (PET) scan
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for patients with solid malignancies
Patients must have measurable disease according Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
Patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Participants must have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in the dose escalation portion of the trial. Participants in the expansion cohort must have measurable disease per RECIST version 1.1 or disease evaluable by assessment of tumor antigens.
Patients must have measurable/evaluable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable or evaluable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
At least one measurable disease lesion according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Version 1.1, 2009);
PHASE II SCLC: Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors, version (RECIST 1.1)
Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Have measurable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.
Measurable disease as defined by immune related Response Criterion (irRC) or Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
At least two measurable lesions (including the index lesion) according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version (v)1.1
The patient must have radiographic measurable disease per Response Evaluation Criteria in Solid Tumor version 1.1 (RECIST 1.1) criterion
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
CAPMATINIB INCLUSION CRITERIA: Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors Version (RECIST)1.1
Subject must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) (version [v]1.1)
Have at least one tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumors (RECIST version [v]1.1)
Arms 1E, 2E, 3E: patients with at least one measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 that have not been previously irradiated
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Measurable or non-measurable (but evaluable) disease as defined via Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Measurable disease, that is, presenting with at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST version 1.1).
Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
Has measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Additional Inclusion Criteria for Dose Finding Part and Dose Expansion Part:
Subjects who have measurable disease according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST version 1.1).
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.
Patients must have histologically or cytologically confirmed stage IIIB or IV NSCLC with radiographic proof of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for solid tumors
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 for solid tumors, within 28 days prior to registration
Participant must have measurable disease, as defined per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 per the Central Radiographic Assessment Committee (CRAC).
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
At least one measureable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Have 2 or more measurable sites of disease as defined by either Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), or cutaneous lesions at least 1 cm in greatest dimension
Measurable disease per disease specific Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1-patients with bone as their only site of disease will not be eligible
Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1
All sites of disease must be evaluated within 4 weeks prior to randomization; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Participants in the randomized portion of the study must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 criteria.
measurable and/or non-measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Disease must be measurable by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
For the dose-escalation phase, measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 (v1.1) is permitted; for the dose expansion phase, patients must have measurable disease by RECIST v1.1
Have measurable disease or nonmeasurable but evaluable disease as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 or other tumor-specific criteria or disease assessable by physical exam or other methods if not measurable by RECIST
Measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) criteria
Participants must have measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Has at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Subjects who have evaluable lesion per guideline of Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Dose Expansion Phase: at least one measureable lesion as defined by RECIST [Response Evaluation Criterion in Solid Tumors] version 1.1.
Measurable disease using clinically appropriate criteria for the type of malignancy, RECIST version 1.1 for solid tumors and Cheson 2007 for lymphoma
Evidence of measurable disease at screening as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)
Both measurable as well as non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 will be allowed
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria (for solid tumors) or equivalent criteria (for patients with non-solid tumor malignancies)
Measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) criteria Version 1.1.
Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1
Measureable tumor by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1
Have measurable disease at the time of study enrollment as defined by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).
All sites of disease must be evaluated within 4 weeks prior to beginning therapy; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)
Measurable disease by response evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1) prior to the administration of study treatment
Expansion Phase only: Has measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Version 1.1, 2009), ie, has at least one measurable lesion
Subject has measurable or nonmeasurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Disease must be measurable with at least 1 uni dimensional measurable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
All sites of disease must be evaluated within 4 weeks prior to beginning therapy; patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Participant has radiographically-documented measurable disease, as per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1).
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable disease at the time of study entry as defined by Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1).
The participant has metastatic disease or locally advanced disease that is measurable or nonmeasurable, but is evaluable disease by radiological imaging per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
Subject has radiological documented measurable disease (ie, at least one measureable lesion as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1).
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1
At least one measureable lesion as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
Measurable or evaluable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1 (v 1)
Have measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST, v1.1)
Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per response evaluation criteria in solid tumors version (RECIST) 1.1 criteria
Patients must have measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1])
Measurable or non-measurable disease is permitted as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) for phase 1b; for phase 2, patients must have measurable disease as defined in RECIST v1.1
At least 1 lesion on a computed tomography (CT) scan that is measurable as defined by Response Evaluation Criteria In Solid Tumors (RECIST), Version 1.1.
Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 guidelines or evaluable disease; bone metastases must be evaluable
Patients must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
At least one measurable lesion and/or non-measurable disease evaluable according to Response Evaluation Criteria In Solid Tumors Version 1.1
At least one measurable lesion according to response evaluation criteria in solid tumours version 1.1
Presence of at least one site of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1
Patients must have measurable disease as per the revised Response Evaluation Criteria In Solid Tumors (RECIST) criteria (version 1.1)
Measurable (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]) indicator lesion not previously irradiated
Has measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 confirmed by CT or MRI scan within 28 days prior to enrollment.
Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Measurable or evaluable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v) 1.1 mRECIST or elevated AFP
All patients must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1
Part 2/Dose Expansion Only: Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1
Measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)
Subjects must have at least 1 measurable or evaluable tumor lesion according to RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, version 1.1)
Measurable and/or evaluable disease as per the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1) [Groups 1, 2 of Part A and Group 3 of Part B] Inclusion Criteria Part A: MAD
Eligible study subjects must have histologic or cytologic confirmation of advanced, unresectable or metastatic solid tumors, and have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. All scans and x-rays used to document measurable disease must be done within 28 days before enrollment (ascites and bone lesions are not considered measureable disease).
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. All scans and x-rays used to document measurable disease must be done within 28 days before enrollment (ascites and bone lesions are not considered measureable disease).
Participants must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria; baseline measurements and evaluation of ALL sites of disease must be obtained within 4 weeks prior to registration
Measurable disease defined as 1 or more target lesions according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. At least one measurable lesion must be in the lungs.
Radiologically measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Measurable and/or evaluable disease based on Response Evaluation Criteria in Solid\n             Tumors (RECIST version 1.1)
Patients must have measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Has measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
For escalation: documentation by established staging studies or clinical examination to have measurable or non-measurable metastatic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) on imaging studies CT
At least one measurable lesion according to Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1
Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Evaluable disease or disease measurable per modified Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Patients must have measurable disease as defined by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); baseline measurements must be obtained within 4 weeks prior to initiating therapy; at least 1 of the tumor sites must be amenable to surgical or core biopsy
Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Patients may have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) criteria version (v.) 1.1 or non-measurable tumors
Metastatic disease documented on diagnostic imaging studies with measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1
Measurable disease according to Response Criteria for Solid Tumors (RECIST Version 1.1)
Participants must have measurable disease by response evaluation criteria in solid tumors (RECIST) version (v) 1.1 or bone-only disease with radiologic scans
Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) (for phase II part only)
The participant has measurable or nonmeasurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 guidelines.
Patients must have computed tomography (CT) measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Participants must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens:
Measurable disease by CT or MRI per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) criteria
Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Have measurable disease based on RECIST version (v) 1.1 for solid tumors
Must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 regardless of disease stage (e.g. localized, locally advanced, or metastatic)
At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
Has measurable disease based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by local radiology review.
Subject must have evaluable, progressive, and measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, Version 1.1
